Cibus (CBUS) Accumulated Expenses (2016 - 2026)
Cibus (CBUS) posted Accumulated Expenses of $3.1 million for Q4 2025, up 15.29% sequentially from $2.7 million in Q3 2025, and down 7.49% YoY from $3.3 million in Q4 2024.
Cibus (CBUS) Accumulated Expenses (2016 - 2026) Analysis & Trends
Cibus has reported Accumulated Expenses for 10 years, with the latest figure at $3.1 million in Q4 2025.
- Quarterly Accumulated Expenses fell 7.49% year-over-year to $3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (down 7.49% YoY) and the FY2025 annual result came in at $3.1 million, down 7.49% from the prior year.
- Accumulated Expenses climbed to $3.1 million in Q4 2025 per CBUS's latest filing, from $2.7 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $5.0 million in Q2 2023 and troughed at $107000.0 in Q4 2022.
- A 5-year average of $2.3 million and a median of $2.6 million in 2025 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2023: Accumulated Expenses plunged 88.74% in 2022, then surged 3505.61% in 2023.
- Over 5 years, Accumulated Expenses stood at $339000.0 in 2021, then tumbled by 68.44% to $107000.0 in 2022, then soared by 3505.61% to $3.9 million in 2023, then retreated by 14.23% to $3.3 million in 2024, then dropped by 7.49% to $3.1 million in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $3.1 million, $2.7 million, and $3.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.61 Mn |
| Dec 31, 2025 | 3.06 Mn |
| Sep 30, 2025 | 2.66 Mn |
| Jun 30, 2025 | 3.12 Mn |
| Mar 31, 2025 | 2.57 Mn |
| Dec 31, 2024 | 3.31 Mn |
| Sep 30, 2024 | 3.23 Mn |
| Jun 30, 2024 | 3.68 Mn |
| Mar 31, 2024 | 3.30 Mn |
| Dec 31, 2023 | 3.86 Mn |
| Sep 30, 2023 | 3.70 Mn |
| Jun 30, 2023 | 5.04 Mn |
| Mar 31, 2023 | 1.05 Mn |
| Dec 31, 2022 | 107,000.00 |
| Sep 30, 2022 | 380,000.00 |
| Jun 30, 2022 | 262,000.00 |
| Mar 31, 2022 | 379,000.00 |
| Dec 31, 2021 | 339,000.00 |
| Sep 30, 2021 | 1.14 Mn |
| Jun 30, 2021 | 2.33 Mn |